Breath test targets TB (tuberculosis)
This article was originally published in Clinica
A US team is developing an "electronic nose" for detecting tuberculosis (TB) from a breath sample. The portable device may provide instant results and cut the costs associated with the traditional TB skin test, which takes several days to produce a result, claim researchers from the Illinois Institute of Technology in Chicago.
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.